In our study, we decided to focus only on cannabinoid receptor 2 agonists since only a small number of preclinical studies have evaluated the impact of CB2 agonists and their effects following long-term treatment on tumor growth and cancer cell proliferation (Hanlon et al., 2016; Elbaz et al., 2017). This evidence concerns the gene CNR2 and neoplasm.